FDA Approves IGALMI as First At-Home Treatment for Agitation Associated With Schizophrenia and Bipolar Disorder in Adults

Teva Pharmaceuticals announced on November 16 that the U.S. Food and Drug Administration (FDA) has approved IGALMI (dexmedetomidine) sublingual film for at-home use. With the approval, IGALMI becomes the first FDA-approved treatment that can be used at home for acute agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder in adults.
Agitation is a common acute symptom of these conditions, marked by tension, restlessness and increased activity, and episodes can escalate quickly. According to Teva, agitation affects between 25% and 40% of patients across these conditions, and in up to 21% of cases an episode results in an emergency department visit or hospitalization. Until now, approved treatments generally had to be given in a healthcare setting or under the supervision of a healthcare provider, leaving patients without an approved option they could use themselves when an episode occurred at home.
The approval is supported by the Phase 3 SERENITY At-Home Safety and Tolerability Trial, a randomized, double-blind, placebo-controlled 12-week study in which 1,160 agitation episodes in 102 patients were treated with IGALMI. The trial met its primary endpoint of safety and tolerability in the at-home setting, tolerability remained consistent with repeat dosing, and there were no discontinuations due to tolerability. The most commonly reported adverse events were somnolence, dry mouth, dizziness, and oral paresthesia or oral hypoesthesia.
Chris Fox, Executive Vice President, U.S. Commercial and Head of Innovative Franchise at Teva, said the first FDA-approved at-home treatment for agitation associated with these conditions gives patients and caregivers an important new option in the setting where episodes often occur. Eric Hughes, M.D., Ph.D., Executive Vice President, Global R&D and Chief Medical Officer at Teva, said being able to treat agitation symptoms when they start gives patients and caregivers an important new way to manage these episodes.
Teva acquired IGALMI in late October 2026. The application for at-home use was submitted on January 14, 2026, as a supplemental New Drug Application building on the product's existing approval for use under healthcare provider supervision. Teva said it will announce commercialization plans for IGALMI for at-home use at a later date.
(Source: Teva)
Source: Teva
Published by GSM · USA (original Chinese edition)
Photo: 图:美国食品药品监管局(FDA)总部大楼入口。FDA 官方图,公共领域,经 Wikimedia Commons。 / Photo: Entrance of the U.S. Food and Drug Administration headquarters. FDA official photo, public domain, via Wikimedia Commons.

